The Evidence

Why this person — and not the person beside them? Susceptibility, genetics, and the uneven risk of MCS

Exposure alone does not explain MCS. The evidence points toward an exposure-plus-susceptibility problem: people sharing the same building, workplace, or deployment can have very different outcomes. Genetics, prior exposures, autonomic state, immune biology, infections, and other vulnerabilities are candidates, but no single susceptibility factor explains the population.

Exposure alone does not explain MCS. The harder question is why similar environments leave some people unaffected while others develop persistent chemical intolerance.

Exposure is only half the story

Two people can work in the same building, live in the same house, or share a deployment and come away with very different health outcomes. That fact does not weaken the environmental model of MCS. It tells us that susceptibility matters.

In environmental medicine, this is normal rather than exceptional. Smoking does not give every smoker lung cancer. A virus does not produce the same long-term syndrome in every infected person. The same medication can be harmless to one person and dangerous to another. Biology is full of interactions between exposure and host susceptibility.

MCS research therefore has to ask two questions at once: what happened in the environment, and what was different about the person who became persistently intolerant?

Why family clustering matters

When more than one person in a family develops unusual chemical or environmental intolerance, the obvious question is whether susceptibility is inherited. That is scientifically reasonable, but family clustering can arise from shared genes, shared environments, shared occupations, shared homes, learned behaviors, or some combination of them.

The existing literature is too thin to assign a percentage of MCS to heredity. One small 1999 family-history study of 15 MCS subjects reported that nearly 30 percent of their relatives were said to have MCS, but relatives were reported by participants rather than independently examined, and the study was designed around psychiatric family history rather than rigorous MCS phenotyping. It is a clue, not a prevalence estimate.

What we know from MCS genetics

One of the most cited MCS genetic studies compared 203 cases with 162 controls and examined variants in enzymes involved in chemical metabolism, including CYP2D6, NAT1, NAT2, PON1, PON2, and MTHFR. The investigators reported associations involving CYP2D6, NAT2, and PON1 and concluded that genetically variable biotransformation pathways deserved further study.

That was an intriguing result, not a genetic explanation of MCS. The authors themselves said replication was needed.

Later research did not consistently reproduce those associations. A Danish study of 96 MCS patients and 1,207 population controls found no significant association with the selected metabolic-gene variants. Another case-control study of self-reported MCS similarly found no significant differences in several of the same genes.

The 2010 Danish replication tested several of the same candidate genes in 96 MCS patients and 1,207 population controls: PON1 and MTHFR were not associated, the CYP2D6 pattern was not statistically significant, and only limited or post-hoc signals appeared for other variants. A 2025 small exome study examining SLC-family genes is an example of the field moving toward broader genetic architecture, but its sample is far too small to establish a general MCS genotype. What CYP2D6, NAT2, GST and MTHFR findings do and do not show is set out on this site’s gene-variants page.

The right conclusion is not “MCS is genetic” or “genetics do not matter.” It is that simple candidate-gene explanations have been inconsistent, while inherited susceptibility remains biologically plausible and worth studying with better methods.

What Gulf War illness adds to the question

Gulf War illness is not MCS, but it provides an important model of exposure interacting with susceptibility. In a 2022 national case-control study, 508 Gulf War illness cases and 508 controls were evaluated for a prespecified interaction between PON1 Q192R status and estimated low-level nerve-agent exposure. The study reported a gene-environment interaction consistent with the idea that the same exposure may have different consequences depending on PON1 biology.

A 2024 multisite study of 295 Gulf War illness cases and 103 veteran controls found a more complex pattern: associations between particular Gulf War exposures and illness differed across PON1 subgroups. Again, this does not prove that PON1 causes MCS. It demonstrates the kind of exposure-by-susceptibility interaction that MCS researchers should be looking for rather than expecting one exposure to affect every person identically.

PON1 is biologically interesting because paraoxonase activity affects the metabolism of some organophosphate compounds, which creates a mechanistic bridge worth investigating for pesticide- or nerve-agent-exposed subgroups. But a biologically plausible gene is not an MCS gene. The correct model is susceptibility: genetic differences may alter the probability or phenotype of illness after an environmental event.

Susceptibility is probably larger than genetics

Genes are only one layer. Susceptibility could involve prior toxicant exposure, infection, hormonal state, age, immune regulation, mast-cell biology, autonomic regulation, small-fiber function, oxidative or metabolic reserve, previous neurological injury, epigenetic changes, or combinations we have not yet identified.

This is where the family stories reported by many patients become scientifically interesting but not yet conclusive. A family may share genes, but it also shares homes, occupations, products, diets, infections, and cultural patterns. Family clustering is a clue that should be measured, not proof of inheritance.

The high-gain hypothesis

Our working model is that some people may be more capable of entering — or less capable of leaving — an acquired high-gain environmental-response state after a sufficient initiating event or period of exposure.

That state could involve sensory receptors such as TRPA1 and TRPV1, peripheral or small-fiber nerves, central sensory processing, autonomic regulation, inflammatory signaling, mast-cell pathways, redox biology, and learned amplification after the illness exists. No single pathway has earned the right to be called “the cause.”

The strength of this model is that it allows multiple levels of biology to interact. It also makes testable predictions: susceptible people should differ in measurable ways from exposed people who never become chemically intolerant.

What the registry is answering

The Canary Registry should collect family history, occupation, major exposure history, infection and medical-event chronology, prior TBI and PTSD, migraine, asthma, MCAS, POTS/dysautonomia, ME/CFS, fibromyalgia, Long COVID, medication intolerance, and sensory sensitivities. Those variables should be collected neutrally and analyzed as possible susceptibility markers, not declared causes in advance.

Participants who are willing can later be recruited into phenotype studies involving autonomic testing, small-fiber assessment, quantitative sensory testing, genetics or epigenetics, inflammatory or redox measures, and carefully designed exposure studies.

The ideal comparison is not simply MCS versus healthy controls. It is MCS versus people with similar documented exposures who did not develop MCS. That is the comparison most capable of answering “why this person?”

Where we stand

Environmental exposure and individual susceptibility are not rival explanations. They are likely parts of the same causal problem.

Current MCS genetics are too inconsistent to identify a susceptibility gene or genetic test. But gene-environment work in related exposure illnesses, combined with the uneven distribution of MCS after similar exposures, makes susceptibility one of the central research questions.

We should stop expecting a single universal vulnerability and start looking for combinations of biological traits that predict who crosses from ordinary exposure into persistent environmental hyperresponsiveness.

We followed the evidence. Here’s where it leads →

Sources

Sources

Study populations and limitations are described above; inclusion does not mean every study used the 1999 consensus case definition.

1McKeown-Eyssen G et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004;33(5):971-8. PMID: 15256524. DOI: 10.1093/ije/dyh251
2Berg ND et al. Genetic susceptibility factors for multiple chemical sensitivity revisited. Int J Hyg Environ Health 2010;213(2):131-9. PMID: 20185366. DOI: 10.1016/j.ijheh.2010.02.001
3Wiesmüller GA et al. Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): a case-control study. J Toxicol Environ Health A 2008;71(11-12):786-94. PMID: 18569577. DOI: 10.1080/15287390801985620
4Black DW et al. Psychiatric illness in the first-degree relatives of persons reporting multiple chemical sensitivities. Toxicol Ind Health 1999;15(3-4):410-4. PMID: 10416293. DOI: 10.1177/074823379901500315
5Alcorta E, Gomez-Diaz C. Multiple Chemical Sensitivity and the SLC Gene Superfamily: A Case-Control Study. Int J Mol Sci 2025;26(13). PMID: 40650259. DOI: 10.3390/ijms26136484
6Haley RW et al. Evaluation of a Gene-Environment Interaction of PON1 and Low-Level Nerve Agent Exposure with Gulf War Illness: A Prevalence Case-Control Study Drawn from the U.S. Military Health Survey's National Population Sample. Environ Health Perspect 2022;130(5):57001. PMID: 35543525. DOI: 10.1289/EHP9009
7Steele L et al. PON1 Status in Relation to Gulf War Illness: Evidence of Gene-Exposure Interactions from a Multisite Case-Control Study of 1990-1991 Gulf War Veterans. Int J Environ Res Public Health 2024;21(8). PMID: 39200575. DOI: 10.3390/ijerph21080964
← Back to MCSDisability.com
↑